Op2Lysis signs a partnership agreement with Inserm and University of Caen

Op2Lysis signs a partnership agreement with Inserm and University of Caen

A partnership agreement has been signed by Op2Lysis with Inserm research unit U1237 and University of Caen. This academic laboratory is focused on stroke research, from research on pathophysiological mechanisms to the identification of innovative therapeutic options.

This partnership is the logical next step, as it follows research activities leaded in this research unit over more than 10 years by Jérôme Parcq, cofounder of Op2Lysis. The resulting share of human and technological assets will help moving forward O2L-001 development towards clinical stage, and will allow initiation of new research programs.

This cooperation established by Op2Lysis and Inserm and University of Caen will favor success in our fight against the severe consequences of hemorrhagic strokes
————————————
To know more, please click on the following:

The origin of Op2Lysis 
Our product O2L-001 
Inserm Unit (U1237)

About the author

Tiffany Le Carff administrator